Purpose: To develop 3D high-resolution imaging of 2-hydroxyglutarate (2HG) at 3T in vivo. Methods: Echo-planar spectroscopic imaging with dual-readout alternated-gradients (DRAG-EPSI), which was recently reported for 2D imaging of 2HG at 7T, was tested for 3D imaging of 2HG at 3T. The frequency drifts and acoustic noise induced by DRAG-EPSI were investigated in comparison with conventional EPSI. Four patients with IDHmutant gliomas were enrolled for 3D imaging of 2HG and other metabolites. A previously reported 2HG-tailored TE 97-ms PRESS sequence preceded the DRAG-EPSI readout gradients. Unsuppressed water, acquired with EPSI, was used as reference for multichannel combination, eddy-current compensation, and metabolite quantification. Spectral fitting was conducted with the LCModel using in-house basis sets. 
| INTRODUCTION
The identification of 2-hydroxyglutarate (2HG) by 1 H MRS in patients with isocitrate dehydrogenase (IDH) mutant gliomas is a major breakthrough in neuro-oncology imaging. 2HG is the first imaging biomarker that is specific to a genetic mutation in gliomas, 1 making the diagnosis of IDH mutant gliomas possible without surgery. 2HG also has a significant predictive value with respect to the stage and survival in gliomas because IDH mutation carries a favorable prognosis. 2, 3 Gliomas are highly heterogeneous and infiltrative. Their clinical course is characterized by progression to a higher histological grade and recurrence beyond the borders of the initial tumor mass. The need of a surveillance technique for use in extended areas of the tumor is a high priority. The tumor cellularity and the IDH activity may vary within a tumor mass, therefore the spatial distribution of 2HG level may be nonuniform. A 3D imaging platform to measure 2HG rapidly is an outstanding strength for monitoring IDH-mutant tumors.
With the ability to detect 2HG by high-resolution 3D MRS imaging, this metabolite could be used to follow patients with much greater accuracy. Although several single-voxel MRS methods were proposed for in vivo detection of 2HG in patients at 3T, [4] [5] [6] and the methods are translated into many hospitals and used for patient care, multi-voxel MRS imaging of 2HG, in particular 3D high-resolution imaging, remains as a challenge. In 2012, Choi et al. 4 presented 2HG mapping in a glioma patient using phase-encoded CSI. Although this prior study showed that 2HG can be imaged at clinically acceptable resolution (voxel size = 10 × 10 × 15 mm 3 ) with similar detectability as in single-voxel MRS, the application was limited to 2D imaging because 3D imaging by CSI modality is not practically feasible because of its long scan time. Recently, Andronesi et al. 8 reported 3D imaging of 2HG using a spiral spectroscopic imaging technique combined with J-difference editing. 7 The resolution was relatively low (voxel size = 20 × 20 × 20 mm 3 ). The image data processing could be complicated with need of much efforts for off-resonance correction for spiral reconstruction 9 and additionally estimation of the 2HG target resonance (4.0 ppm), which is close to the water resonance, may be susceptible to subtraction errors when water suppression is suboptimal. Recently, we reported a new MRS imaging scheme, dubbed echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI). 10 In this prior study, the method was used for 2D imaging of 2HG at 7T, with inplane resolution of 6 × 6 mm 2 . In DRAG-EPSI, the timedomain MRS signals are constructed with combined analysis of data obtained with 2 sets of bipolar echo-planar readout gradients. Compared to conventional EPSI, the dwell time of DRAG-EPSI is smaller by 50% for identical readout-gradient strengths, providing a 2-fold increase in spectral width, as shown in the 7T study. At 3T, at which the spectral width of conventional EPSI may be large enough for covering the spectral region of interest, DRAG-EPSI can be used for similar-quality imaging using reduced readout-gradient strengths. This may alleviate frequency drifts and acoustic noise and possibly improves the data quality and subject compliance. When compared to CSI, the benefit of EPSI may be fully realized when metabolites are imaged for large data matrix size (e.g., 3D imaging). In the present study, we demonstrate the fidelity of DRAG-EPSI for 3D high-resolution imaging of 2HG and other brain metabolites using patient-friendly readout-gradient strengths.
| METHODS
MR experiments were carried out in a human wholebody 3T MR scanner (Philips Medical Systems, Best, the Netherlands) using a whole-body quadrature transmit coil and a 32-channel receive head coil (Nova Medical, Wilmington, MA). The gradient system offered maximum amplitude of 40 mT/m, with maximum slew rate of 200 mT/m/ms. In vitro EPSI experiments were performed in a 17-cm diameter GE Braino phantom to assess the frequency drifts and acoustic noise induced by the readout gradients. Four glioma patients were enrolled, who included an IDH1-mutated grade-II oligoastrocytoma (26-year-old female), an IDH1-mutated grade-II oligodendroglioma (43-year-old male), an IDH1-mutated grade-III astrocytoma (38-year-old male), and an IDH2-mutated grade-IV glioblastoma (31-year-old male). The protocol was approved by the Institutional Review Board of the University of Texas Southwestern Medical Center. Written informed consent was obtained from subjects before MR scans.
3D DRAG-EPSI was preceded by prescription of a volume of interest (VOI) using a previously reported 3T 2HG-optimized TE 97ms PRESS sequence. 4 The PRESS sequence included a 5.8 ms 73° excitation RF pulse (bandwidth 2.5 kHz) and two 13. The 3D k-space data were zero filled to 48 × 36 × 16 matrix and subsequently apodized with a 3D Hamming function. The time domain data were zero filled to 2048 points and apodized with a 2-Hz exponential function. Eddy-current compensation and multi-channel combination were conducted using the unsuppressed PRESS DRAG-EPSI water as reference, after which the 2 sets of interleaved data were combined without additional phase correction, similarly as in our prior study. 10 Spectral fitting was performed between 1.1 and 3.7 ppm, with LCModel software, using in-house calculated basis spectra of 14 metabolites, which included 2HG, Glu, NAA, mI, Lac, Gln (glutamine), tCr (Cr + phosphocreatine), Gly (glycine), GSH (glutathione), Ace (acetate), Asp (aspartate), sI (scyllo-inositol), NAAG (N-acetylaspartylglutamate), and tCho (glycerophosphorylcholine + phosphorylcholine). Because the T 2 difference between tumor and normal brain is much larger in water than in metabolites, 11 the metabolite signal estimates from LCModel were normalized to the unsuppressed short-TE (14 ms) water for individual voxels, by which the data were corrected for potential B 1 variations. Subsequently, the metabolite concentrations were calculated by scaling the normalized metabolite signal estimates with reference to tCr in normal-appearing gray-matter region at 8 mM. 12, 13 Metabolite estimates with CRLB >20%
were discarded, similarly as in prior EPSI studies. 8, 14, 15 All data are presented as mean ± SD.
| RESULTS
We compared the frequency drifts induced by DRAG-EPSI with those of conventional EPSI in a phantom solution. The spectral width was set to be similar between conventional EPSI and DRAG-EPSI (987 Hz vs. 1037 Hz). Because the spectral width in DRAG-EPSI was determined by the time interval between the adjacent odd and even number echoes, DRAG-EPSI needed much lower readout gradient strength and slew rate than conventional EPSI, as shown in Figure 1A . For each EPSI, 40 images were acquired for 20 min, and subsequently the drifts of water resonance frequency were calculated with reference to the first imaging scan. The frequency drift averaged over the voxels within the phantom was much smaller (5.5-fold) in DRAG-EPSI than in conventional EPSI (7.0 ± 1.0 vs. 38.8 ± 1.0 Hz) ( Figure 1B) , which was most likely because of the differences in readout gradient strength and slew rate. With a real-time frequency-drift correction tool (Frequency Stabilization), the frequency drift in DRAG-EPSI was further reduced to 1.1 ± 0.4 Hz ( Figure 1B) . Because of the difference in the readout gradient strength and slew rate, the acoustic noise of DRAG-EPSI was much less compared to conventional EPSI. When measured using a microphone placed within the receive head coil, the sound pressure level in DRAG-EPSI was 63 dB, smaller by 25 dB compared to conventional EPSI (88 dB) ( Figure 1C) . The DRAG-EPSI with 2HG-tailored PRESS prescription was used for imaging of 2HG and other metabolites in 4 patients with IDH-mutant gliomas. For a patient with IDH1-mutant grade-II oligoastrocytoma, T 2 w-FLAIR identified a solid tumor mass in the left medial-occipital region (Figure 2 ). In spectra from the tumor, the 2HG signal at 2.25 ppm was well discernible, whereas the Glu 2.35 ppm signal, which was very large in spectra from the normal-appearing contralateral brain, was small. For a VOI of 100 × 100 × 65 mm 3 , which included the tumor and contralateral normal-appearing brain, the maps of 2HG showed that the volume with elevated 2HG agreed well with the T 2 w-FLAIR hyperintensity volume. The 2HG estimate was as high as 5 mM in the center of the tumor, whereas normal-appearing brain showed essentially null 2HG (<0.5 mM). tCho was substantially high in the tumor compared with normal-appearing brain regions (3.4 vs. 1.9 mM; P < 0.001). The tNAA and Glu levels were both decreased in the tumor. Lac was highly elevated (>10-fold) in the tumor, indicating markedly increased glycolysis in the tumor. Figures 3 and 4 present 3D DRAG-EPSI data from 3 postsurgery patients with IDH mutant gliomas. T 2 w-FLAIR imaging showed lesions outside the resection cavities in all 3 cases. 2HG was measured to be up to 3, 6, and 6 mM in the lesions of the 3 patients (CRLB of 6%, 5%, and 6%, respectively), indicating the lesions were all recurrent tumors. In all 3 cases, the tumors also showed increased tCho and Lac, as indicated in the 3D maps. For an oligodendroglioma patient (Figure 3, left) , the coronal T 2 w-FLAIR images showed 2 distinct tumor masses, among which 2HG was clearly detectable only in the lower part. In contrast, for an astrocytoma patient (Figure 3 , right) who also had 2 distinct tumor masses, 2HG was measurable in both anterior and posterior regions of the tumor mass, as seen in the sagittal image. In a glioblastoma patient (Figure 4) , the 2HG level was higher in the anterior part of the tumor mass than in other regions within the tumor, and the high-2HG regions were consistent 
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| DISCUSSION AND CONCLUSION
We demonstrate 3D high-resolution imaging of 2HG and other metabolites in brain tumor subjects at 3T, which was achieved using a newly developed 3D DRAG-EPSI scheme together with a previously reported 2HG-tailored TE 97 ms PRESS sequence. To our best knowledge, this is the first report of 3D imaging of 2HG with resolution of 10 × 10 × 10 mm 3 , which is the same resolution as in prior EPSI studies of relatively large metabolite signals (e.g., NAA, tCr, and tCho). As shown in our phantom study, the frequency drift induced by DRAG-EPSI was much smaller compared with conventional EPSI (7 vs. 39 Hz during a 20-min scan). This was most likely because of the use of relatively low gradient strengths in DRAG-EPSI given that gradient pulses cause heating in the shimming coil and consequently changes in the B 0 fields. 16 It is noteworthy that in our in vivo scans, the frequency drifts were essentially negligible (≤1 Hz) with the use of a vendor-supplied real-time frequency-drift correction tool, and therefore our 3D imaging data may not have considerable artifacts associated with frequency drifts, obviating the need for correction of frequency instabilities that was incorporated in a prior EPSI study. 16 The reduction in acoustic noise in DRAG-EPSI is highly beneficial for patient scans. Brain tumor patients often show seizure activities. The seizure incidence can be increased by extensive noise during an imaging scan. In practice, at the beginning of our development of high-resolution 2HG imaging, we were using a conventional EPSI scheme (shown in Figure 1A ) and a tumor patient who was sensitive to acoustic noise developed a seizure immediately after the scan. This incident prompted us to develop a new imaging tool with much lower acoustic noise level. We believe improvement in patient comfort by reduced acoustic noise may also be helpful for minimizing potential subject movement and eventually improving the imaging data quality. In reality, the reduction of acoustic noise by 25 dB using DRAG-EPSI ( Figure 1C ) was greatly beneficial for 2HG imaging, as no adverse event was observed during the study, and no complaint about the acoustic noise was received from the patient volunteers. Several researchers reported imaging of 2HG in patients with IDH-mutant gliomas at 3T. In two Choi et al. voxel size (8 mL), Jafari-Khouzani et al. 7 reported larger volumes with elevated 2HG than T 2 w-FLAIR volumes and partial agreement on the locations of the 2 volumes in more than half of the patients. The discrepancy in tumor volumes and locations between 2HG imaging and T 2 w-FLAIR could be because of the large difference in the spatial resolution of images (8 mL vs. 0.001 mL). Published data showed great potential of 2HG imaging for monitoring disease progression 17 and treatment effects 8, 17 in IDH-mutant gliomas, indicating that the 2HG level may be closely related to the clinical behavior of IDH-mutant tumors. Intermediate to high-grade gliomas are highly infiltrative. Following a gross total resection, tumors typically recur adjacent to the resection cavity. The capability to image 2HG at high resolution in 3D space can provide a tool for following IDHmutant glioma patients with high accuracy, which was the primary goal of the present study. DRAG-EPSI requires 2 excitations per k-space point at minimum. This may be acceptable for imaging of 2HG, whose signal is relatively small and may require some averaging for achieving acceptable SNR. Imaging of unsuppressed water, which is often used for eddy-current compensation, may be prolonged because of the 2-excitation requirement. In the present study, the voxel size of unsuppressed-water DRAG-EPSI imaging was set to 20 × 20 × 10 mm 3 (scan time = 1.92 min)
F I G U R E 4
In vivo 3D DRAG-EPSI data from a post-surgery glioblastoma patient are presented in a similar fashion as in Figure 3 . and the water signal of each voxel was used for correcting the eddy-currenteffects in 4 adjacent voxels of 2HG imaging data, similarly as in prior studies. 18 We believe that the eddy-current effects were properly corrected as the effects in the 4 neighboring voxels were very similar. We used conventional EPSI for imaging short-TE STEAM water because of its shorter scan time (0.96 min). For whole-brain imaging, FOV may be set to be larger compared to the present study (240 × 180 × 160 mm ). The increased FOV requires 2-fold larger number of phase-encoding gradients. One may consider changing the number of signal averages from 4 to 2, which may maintain both the 2HG imaging scan length and the SNR. The water imaging scan time may be kept acceptable by reducing the TR and/or the spatial resolution. In addition, the VOIs of the present study were relatively small (120 × 120 × 65 mm 3 or smaller) and therefore may not be ideally applicable for large tumor masses. Imaging on small volumes may be practically beneficial for improving the spectral quality, which may include proper B 1 calibration and B 0 shimming, acceptable water suppression, and minimal lipid contamination across the voxels within the VOI. We therefore chose relatively small VOIs for imaging in tumors, similarly as in several prior studies. 8, 19, 20 In conclusion, we demonstrate in vivo imaging of 2HG in glioma patients using EPSI with dual bipolar readout alternated gradients (DRAG-EPSI). 3D imaging of 2HG with acquisition resolution of 10 × 10 × 10 mm 3 represents a major improvement over prior 2HG imaging methods. Compared with conventional EPSI, DRAG-EPSI needs much smaller readout gradient strengths and induces much less frequency drifts and lower acoustic noise, which may contribute to higher-quality imaging of 2HG in brain tumor patients.
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